Follow us for updates
© 2022
Read the Story →

Pfizer, Moderna Booster Efficacy Wanes After 4 Months: U.S. CDC

One of the first studies on long-term protection from third jabs.
by Agence France Presse
Feb 12, 2022
Photo/s: Jerome Ascaño

The efficacy of third doses of the Pfizer and Moderna mRNA vaccines wanes substantially by the fourth month after administration, a new study by the U.S. Centers of Disease Control and Prevention (CDC) said Friday.

Though it's now well documented that vaccine efficacy goes down after two doses, relatively little has been published on the duration of protection after a booster.

The new study was based on more than 241,204 visits to the emergency department or an urgent care clinic, and 93,408 hospitalizations, which are more serious, among adults with COVID–like illness during Aug. 26, 2021 to Jan. 22, 2022.


Is COVID Becoming Endemic in the Philippines as Surge Subsides?

GUIDE: VaxCertPH is Accepted in These Countries as Official Travel Document

I Feel Guilty for Infecting My Family with COVID. How Do I Deal With It?

Vaccine efficacy was estimated by comparing the odds of a positive COVID test between vaccinated and unvaccinated patients and using statistical methods to control for calendar week, geographic area, while adjusting for age, the level of local transmission, and patient characteristics like comorbidities.

Continue reading below ↓

During the Omicron-predominant period, vaccine efficacy against COVID-associated emergency department or urgent care visits was 87% during the two months after a third dose, but fell to 66% by the fourth month.

Vaccine efficacy against hospitalization was 91% in the first two months, but fell to 78% by the fourth month after a third dose.

"The finding that protection conferred by mRNA vaccines waned in the months after receipt of a third vaccine dose reinforces the importance of further consideration of additional doses to sustain or improve protection," the authors concluded.

Speaking at a White House COVID briefing on Wednesday, President Joe Biden's top medical advisor Anthony Fauci said it was likely that fourth doses would more likely be needed for subsets of people who mount weaker immune responses, such as the elderly and immunocompromised.

In a separate development Friday, the Food and Drug Administration (FDA) authorized a new lab-grown antibody treatment by pharmaceutical company Lilly called bebtelovimab.

Continue reading below ↓
Recommended Videos

The drug is administered as an intravenous injection over at least 30 seconds and has been green lighted for the treatment of mild-to-moderate COVID among people 12 and over at high risk of severe disease. 

Data supporting the authorization came from a clinical trial that showed the drug has strong promise against Omicron. Lilly's previous antibody treatment was de-authorized by the FDA after it was found to be ineffective against this variant. 

Reportr is now on Quento. Download the app or visit the Quento website for more articles and videos from Reportr and your favorite websites.

Latest Headlines
Read Next
Recent News
An exhibit of paintings she received during the campaign.
With the reopening of several local destinations, this app has never been more timely.
He wins the World's Ugliest Dog Contest.
Third crown for the country in the pageant for trans women.
Some relief from rising prices.
The news. So what? Subscribe to the newsletter that explains what the news means for you.
The email address you entered is invalid.
Thank you for signing up to On Three, reportr's weekly newsletter delivered to your mailbox three times a week. Only the latest, most useful and most insightful reads.
By signing up to newsletter, you agree to our Terms of Service and Privacy Policy.